Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Amicus Therapeutics (FOLD) over the last 3 years, with Q1 2018 value amounting to $353442.0.

  • Amicus Therapeutics' Gains from Sales and Divestitures rose 742004.26% to $353442.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $353442.0, marking a year-over-year increase of 742004.26%. This contributed to the annual value of $318200.0 for FY2017, which is 1287.69% up from last year.
  • Per Amicus Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $353442.0 for Q1 2018, which was up 742004.26% from $318200.0 recorded in Q4 2017.
  • In the past 5 years, Amicus Therapeutics' Gains from Sales and Divestitures registered a high of $353442.0 during Q1 2018, and its lowest value of $4700.0 during Q1 2017.
  • For the 3-year period, Amicus Therapeutics' Gains from Sales and Divestitures averaged around $224508.4, with its median value being $210911.0 (2017).
  • As far as peak fluctuations go, Amicus Therapeutics' Gains from Sales and Divestitures surged by 582.59% in 2017, and later surged by 742004.26% in 2018.
  • Amicus Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $281900.0 in 2016, then increased by 12.88% to $318200.0 in 2017, then rose by 11.08% to $353442.0 in 2018.
  • Its Gains from Sales and Divestitures was $353442.0 in Q1 2018, compared to $318200.0 in Q4 2017 and $210911.0 in Q3 2017.